Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT04184375
Recruiting Not applicable

Cognitive Stimulation for Elderly Bipolar Patients

NCT04184375 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2021-03-04
Last updated
2025-03-17

Condition(s) studied

Bipolar DisorderCognitive ImpairmentAge-related Cognitive Decline

Investigational drug(s) / intervention(s)

cognitive stimulation

cognitive stimulation: Patients participate in one session per week according to the following schedule: * 2 sensory stimulation sessions: identify sensations, emotions, how to manage them. * 2 sessions on association, verbal fluency, and imagination: language as a tool for expression in the face of illness. * 2 voluntary attention sessions: improve daily attention. * 2 sessions of intellectual structuring: stimulating and maintaining memory, carrying out external activities. * 2 sessions of structuring through language: impact on social life. * 2 sessions stimulating the temporal and spatial landmarks: agenda, daily trips.

Study summary

Age is a major risk factor for the development of cognitive disorders and neurodegenerative pathologies. Cognitive disorders during the phases of bipolar disease are known to exist, and alterations increase significantly after the age of 65. Drug treatments seem to have only a limited effect. A cognitive stimulation program has proven his benefit to patients over 65 with neurodegenerative diseases (Israel, 2004). We propose to evaluate this cognitive stimulation program that we have adapted to bipolar disease.

Eligibility

Sex
ALL
Min age
65 Years
Max age
—
Healthy volunteers
No
Pre-Inclusion Criteria: * age \> 65 years old * Diagnosis of bipolar illness for more than 10 years * Euthymic phase * Understands and speaks French * Free, informed and express consent Inclusion Criteria: * Mild to moderate neuro-cognitive impairments (MMS Test : 16 ≤ score \< 26) Exclusion Criteria: * Illiteracy * Patient participating in other therapeutic workshops (e. g. psycho-geriatric day hospital care, etc.) * Persons deprived of their liberty by a judicial or administrative decision * Persons of full age who are subject to a legal protection measure * Persons unable to consent * Persons who are not members of or beneficiaries of a social security scheme * Patient's refusal to participate in the study

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Groupe Hospitalier de la Rochelle Ré Aunis La Rochelle France Recruiting

More Groupe Hospitalier de la Rochelle Ré Aunis trials in France

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04184375 on ClinicalTrials.gov ↗ ← All trials in France